Loading...
Alendronate, an inhibitor of bone resorption that recently became available in the U.S., is a popular treatment for osteoporosis. This report draws attention to an increasingly recognized side effect: esophagitis.
Roughly 470,000 people worldwide had received prescriptions for alendronate as of March 1996. At that point, the manufacturer had received 199 reports of adverse esophageal effects; 51 cases were considered serious or severe, and most patients had ulcerative or erosive esophagitis.
Of the severe cases for whom adequate information was available, most had taken the alendronate tablet with minimal or no water, and had not remained upright within the half-hour after swallowing it. Nearly all the cases occurred within one month of start…